Maintenance erlotinib in advanced nonsmall cell lung cancer: cost-effectiveness in EGFR wild-type across Europe

被引:17
|
作者
Walleser, Silke [1 ]
Ray, Joshua [2 ]
Bischoff, Helge [3 ]
Vergnenegre, Alain [4 ]
Rosery, Hubertus [5 ]
Chouaid, Christos [6 ]
Heigener, David [7 ]
de Castro Carpeno, Javier [8 ]
Tiseo, Marcello [9 ]
Walzer, Stefan [2 ]
机构
[1] Hlth Econ Consultancy, Renens, Switzerland
[2] F Hoffmann La Roche Pharmaceut AG, Basel, Switzerland
[3] Thorac Hosp Heidelberg, Heidelberg, Germany
[4] Limoges Univ Hosp, Limoges, France
[5] Assessment In Med GmbH, Marie Curie Str 8, D-79539 Lorrach, Germany
[6] Hosp St Antoine, Paris, France
[7] Hosp Grosshansdorf, Grosshansdorf, Germany
[8] Univ Hosp La Paz, Madrid, Spain
[9] Univ Hosp Parma, Parma, Italy
来源
CLINICOECONOMICS AND OUTCOMES RESEARCH | 2012年 / 4卷
关键词
nonsmall cell lung cancer; erlotinib; cost-benefit analysis; epidermal growth factor receptor; wild-type; Europe;
D O I
10.2147/CEOR.S31794
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background: First-line maintenance erlotinib in patients with locally advanced or metastatic nonsmall cell lung cancer (NSCLC) has demonstrated significant overall survival and progression-free survival benefits compared with best supportive care plus placebo, irrespective of epidermal growth factor receptor (EGFR) status (SATURN trial). The cost-effectiveness of first-line maintenance erlotinib in the overall SATURN population has been assessed and published recently, but analyses according to EGFR mutation status have not been performed yet, which was the rationale for assessing the cost-effectiveness of first-line maintenance erlotinib specifically in EGFR wild-type metastatic NSCLC. Methods: The incremental cost per life-year gained of first-line maintenance erlotinib compared with best supportive care in patients with EGFR wild-type stable metastatic NSCLC was assessed for five European countries (the United Kingdom, Germany, France, Spain, and Italy) with an area-under-the-curve model consisting of three health states (progression-free survival, progressive disease, death). Log-logistic survival functions were fitted to Phase III patient-level data (SATURN) to model progression-free survival and overall survival. The first-line maintenance erlotinib therapy cost (modeled for time to treatment cessation), medication cost in later lines, and cost for the treatment of adverse events were included. Deterministic and probabilistic sensitivity analyses using Monte Carlo simulation (1000 iterations) were performed. Results: According to the model simulations, first-line maintenance erlotinib compared with best supportive care in EGFR wild-type stable metastatic NSCLC resulted in 4.57 months of life gained (17.82 months for erlotinib versus 13.24 months for best supportive care) and 1.14 months of life without progression gained (erlotinib 4.29 versus best supportive care 3.15), and incremental total costs of erlotinib from (sic)7897 (UK) to (sic)9580 (Germany). The corresponding mean incremental cost per life-year gained of erlotinib ranged between (sic)20,711 (UK) and (sic)25,124 (Germany). Sensitivity analyses confirmed these results. Conclusion: First-line erlotinib maintenance treatment is cost-effective compared with best supportive care in EGFR wild-type stable metastatic NSCLC, irrespective of the country setting.
引用
收藏
页码:269 / 275
页数:7
相关论文
共 50 条
  • [21] Cost-effectiveness of afatinib and erlotinib as second-line treatments for advanced squamous cell carcinoma of the lung
    Zhu, Jun
    He, Wei
    Ye, Ming
    Fu, Jie
    Chu, Yun-Bo
    Zhao, Yi-Yang
    Zhang, Yan-Jun
    Kuo, David
    Wu, Bin
    FUTURE ONCOLOGY, 2018, 14 (27) : 2833 - 2840
  • [22] Cost-effectiveness of Erlotinib versus Docetaxel for Second-line Treatment of Advanced Non-small-cell Lung Cancer in the United Kingdom
    Lewis, G.
    Peake, M.
    Aultman, R.
    Gyldmark, M.
    Morlotti, L.
    Creeden, J.
    de la Orden, M.
    JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2010, 38 (01) : 9 - 21
  • [23] Pemetrexed versus gefitinib as a second-line treatment in advanced nonsquamous nonsmall-cell lung cancer patients harboring wild-type EGFR (CTONG0806): a multicenter randomized trial
    Zhou, Q.
    Cheng, Y.
    Yang, J. -J.
    Zhao, M. -F.
    Zhang, L.
    Zhang, X. -C.
    Chen, Z. -H.
    Yan, H. -H.
    Song, Y.
    Chen, J. -H.
    Feng, W. -N.
    Xu, C. -R.
    Wang, Z.
    Chen, H. -J.
    Zhong, W. -Z.
    Liu, Y. -P.
    Wu, Y. -L.
    ANNALS OF ONCOLOGY, 2014, 25 (12) : 2385 - 2391
  • [24] Cost-effectiveness analysis of the first-line EGFR-TKIs in patients with advanced EGFR-mutated non-small-cell lung cancer
    Aguilar-Serra, J.
    Gimeno-Ballester, V
    Pastor-Clerigues, A.
    Milara, J.
    Trigo-Vicente, C.
    Cortijo, J.
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2022, 22 (04) : 637 - 646
  • [25] Cost-effectiveness of KRAS, EGFR and ALK testing for decision making in advanced nonsmall cell lung carcinoma: the French IFCT-PREDICT.amm study
    Loubiere, Sandrine
    Drezet, Alexandre
    Beau-Faller, Michele
    Moro-Sibilot, Denis
    Friard, Sylvie
    Wislez, Marie
    Blons, Helene
    Daniel, Catherine
    Westeel, Virginie
    Madroszyk, Anne
    Lena, Herve
    Merle, Patrick
    Mazieres, Julien
    Zalcman, Gerard
    Lacave, Roger
    Antoine, Martine
    Morin, Franck
    Missy, Pascale
    Barlesi, Fabrice
    Auquier, Pascal
    Cadranel, Jacques
    EUROPEAN RESPIRATORY JOURNAL, 2018, 51 (03)
  • [26] A phase II study of carboplatin, pemetrexed, and bevacizumab followed by erlotinib and bevacizumab maintenance for non-squamous non-small cell lung cancer with wild-type EGFR (HOT1101)
    Taichi Takashina
    Hajime Asahina
    Satoshi Oizumi
    Noriyuki Yamada
    Masao Harada
    Kei Takamura
    Hiroshi Yokouchi
    Toshiyuki Harada
    Osamu Honjo
    Takahiro Ogi
    Naoto Morikawa
    Ichiro Kinoshita
    Ryoichi Honda
    Kosuke Nakano
    Kenya Kanazawa
    Toraji Amano
    Hirotoshi Dosaka-Akita
    Hiroshi Isobe
    Masaharu Nishimura
    International Journal of Clinical Oncology, 2018, 23 : 1060 - 1069
  • [27] A phase II study of carboplatin, pemetrexed, and bevacizumab followed by erlotinib and bevacizumab maintenance for non-squamous non-small cell lung cancer with wild-type EGFR (HOT1101)
    Takashina, Taichi
    Asahina, Hajime
    Oizumi, Satoshi
    Yamada, Noriyuki
    Harada, Masao
    Takamura, Kei
    Yokouchi, Hiroshi
    Harada, Toshiyuki
    Honjo, Osamu
    Ogi, Takahiro
    Morikawa, Naoto
    Kinoshita, Ichiro
    Honda, Ryoichi
    Nakano, Kosuke
    Kanazawa, Kenya
    Amano, Toraji
    Dosaka-Akita, Hirotoshi
    Isobe, Hiroshi
    Nishimura, Masaharu
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2018, 23 (06) : 1060 - 1069
  • [28] Cost-effectiveness and safety of the molecular targeted drugs afatinib, gefitinib and erlotinib as first-line treatments for patients with advanced EGFR mutation-positive non-small-cell lung cancer
    Kimura, M.
    Yasue, F.
    Usami, E.
    Kawachi, S.
    Iwai, M.
    Go, M.
    Ikeda, Y.
    Yoshimura, T.
    MOLECULAR AND CLINICAL ONCOLOGY, 2018, 9 (02) : 201 - 206
  • [29] Osimertinib in first-line treatment of advanced EGFR-mutated non-small-cell lung cancer: a cost-effectiveness analysis
    Aguilar-Serra, Javier
    Gimeno-Ballester, Vicente
    Pastor-Clerigues, Alfonso
    Milara, Javier
    Marti-Bonmati, Ezequiel
    Trigo-Vicente, Cristina
    Alos-Alminana, Manuel
    Cortijo, Julio
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2019, 8 (11) : 853 - 863
  • [30] Dacomitinib in first-line treatment of advanced EGFR-mutated non-small-cell lung cancer: a cost-effectiveness analysis
    Aguilar-Serra, Javier
    Gimeno-Ballester, Vicente
    Pastor-Clerigues, Alfonso
    Milara, Javier
    Marti-Bonmati, Ezequiel
    Trigo-Vicente, Cristina
    Cortijo, Julio
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2021, 10 (04) : 325 - 335